Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa
Authors: Raugi Dana N , Ba Selly , Cisse Ousseynou , Diallo Khardiata , Tamba Ibrahima Tito , Ndour Cheikh , Badiane Ndeye Mery Dia , Fortes Louise , Diallo Mouhamadou Baïla , Faye Dominique , Smith Robert A , Sall Fatima , Toure Macoumba , Sall ElHadji Ibrahima , Diallo Agne Habibatou , Faye Khadim , Diatta Jean Philippe , Sy Marie Pierre , Chang Ming , Diaw Binetou , Sambou Jacques , Bakhoum Raphael , Sy Mame Demba , Niang Alassane , Malomar Jean Jacques , Coombs Robert W , Hawes Stephen E , Ndoye Ibra , Kiviat Nancy B , Sow Papa Salif , Seydi Moussa , Gottlieb Geoffrey S ,   for the University of Washington–Senegal HIV-2 Study Group, Traore Fatou , Cisse Samba , Ndiaye Ousseynou , Faye Babacar , Simal Fatou , Astou Diop Ndeye , Bale Diop Amadou , Fadam Diome Marianne , Gomis Juliette , Dieye Therese , Benzekri Noelle , Lin John , Kenney Donna , Starling Alison , Critchlow Cathy , Cherne Steve , Song Jennifer , Nixon Robbie , Burhen Pallas , Zavala Chris , Wu Vincent , Masoum Sara , Leong Sally , Montano Alex , Oakes Mariah , Olson Julia , Blankenship Lindsey , Pan Charlotte , Parker Kara , Parker Kate , Hernandez Alex , Church Brad , Kim Moon , Lu Paul , Sorensen Stefanie , Wong Kim , Mullins James 
Published: March 2020

AbstractBackgroundProgrammatic treatment outcome data for people living with human immunodeficiency virus type 2 (HIV-2) in West Africa, where the virus is most prevalent, are scarce.MethodsAdults with HIV-2 initiating or receiving antiretroviral therapy (ART) through the Senegalese national AIDS program were invited to participate in this prospective, longitudinal observational cohort study. We analyzed HIV-2 viral loads, CD4 cell counts, antiretroviral drug resistance, loss to follow-up, and mortality. We also examined changes in treatment guidelines over time and assessed progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets for HIV-2.ResultsWe enrolled 291 participants at 2 sites for 926.0 person-years of follow-up over 13 years. Median follow-up time was 2.2 years per participant. There were 21 deaths reported (7.2%), and 117 individuals (40.2%) were lost to follow-up, including 43 (14.7%) who had an initial visit but never returned for follow-up. CD4 counts and HIV-2 viral suppression (&lt; 50 copies/mL) at enrollment increased over calendar time. Over the study period, 76.7% of plasma viral loads for participants receiving ART were suppressed, and median CD4 gain was 84 cells/μL in participants’ first 2 years on study. Since the UNAIDS 90-90-90 strategy was published, 88.1% of viral loads were suppressed. Fifteen percent of patients experienced virologic failure with no known resistance mutations, while 56% had evidence of multiclass drug resistance.ConclusionsParticipants in the Senegalese national AIDS program are initiating ART earlier in the course of disease, and more modern therapeutic regimens have improved outcomes among those receiving therapy. Despite these achievements, HIV-2 treatment remains suboptimal, and significant challenges to improving care remain.